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Abstract
Sentinel node (SN) status is the most important prognostic factor for
localized melanoma. Usually, patients with Breslow thickness of less
than 1.0 mm are not included in SN protocols. However, the literature
presents a rate ranging from 3 to 7% of nodal recurrence in thin
melanoma. Ulceration, regression and high mitotic rate have been
considered to be indications for an SN biopsy. The metastatic potential
of the vertical growth phase is uncertain. To correlate pathological
features in thin melanoma with SN metastasis, we reviewed 358
patients submitted to SN biopsy. Seventy-seven patients with lesions
of 1 mm or smaller were included in the study group. Histological
evaluation of the primary tumor included thickness, Clark level,
mitotic rate, ulceration, regression, and growth phase. Lymphoscintig-
raphy was performed on all patients. Lymphatic mapping and gamma
probe detection were both used for SN biopsy. Histological examina-
tion of SN consisted of hematoxylin-eosin and immunohistochemical
staining. Median follow-up was 37 months. Six patients had
micrometastases. Statistical analysis by the Fisher test showed that
ulceration (P = 0.019), high mitotic rate (P = 0.008) and vertical
growth phase (P = 0.002) were positively correlated with
micrometastases. If other studies confirm these results, more mela-
noma patients must be submitted to SN biopsy.
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The overall incidence of melanoma has
been rising all over the world. The propor-
tion of thin melanoma has increased as com-
pared to more deeply infiltrating lesions (1-
3). Sentinel node (SN) biopsy proved to be
an accurate staging procedure of regional
nodal status with minimal morbidity and SN
status is the most important prognostic factor
for localized melanoma (4,5).
What does thin metastasizing melanoma
have that confers this phenotype? This is still
an unsolved question. The latest proposed
change of the tumor-node-metastasis (TNM)
cutaneous melanoma classification includes
the presence or absence of ulceration and
Clark level in category “T” (6). Patients with
thin primary melanoma (1 mm) without
ulceration and with a Clark level of less than
IV are expected to have an excellent progno-
sis (7). However, some of these patients with
low risk disease develop recurrence and
death. The literature presents a rate of nodal
recurrence ranging from 3 to 7% in thin
melanoma patients (8-11). Other pathologi-
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cal features such as ulceration, mitotic rate,
regression and vertical growth phase are sup-
posed to play an important role in the deter-
mination of recurrence risk in thin mela-
noma and have been considered as indica-
tors for an SN biopsy (12,13).
The early steps in the development and
progression of malignant melanoma include
proliferation of transformed epidermal mel-
anocytes and their subsequent invasion of
the papillary dermis (radial growth phase).
This can be followed by the vertical growth
phase, a step with metastatic capability (14).
The identification of parameters that might
predict progression and survival is manda-
tory for thin melanoma (1).
In the SN biopsy protocol of our institu-
tions we have included melanoma patients
with thin melanoma. Some of them have
recurred. To address why these patients have
recurred we analyzed the pathological fea-
tures of their primary melanoma, including
vertical growth phase.
Between June 1997 and January 2002,
358 patients with clinically localized cutane-
ous melanoma underwent a successful SN
biopsy, according to protocols approved by
the Ethics Committee of Escola Paulista de
Medicina, UNIFESP, and Hospital Israelita
Albert Einstein. Among them, 77 had le-
sions 1 mm or smaller and formed our study
sample. Informed consent was obtained from
all patients. Clinically node-negative mela-
noma patients were enrolled into our proto-
col if Breslow thickness was 1.0 mm or more
and those with thickness of less than 1.0 mm
with ulceration, more than 5 mitoses/mm2,
regression or Clark level IV or V were also
included. The histological evaluation of the
primary lesion included tumor thickness,
Clark level, mitotic rate, ulceration, regres-
sion, vascular invasion, tumor-infiltrating
lymphocytes, and growth phase. The pres-
ence of vertical growth phase was deter-
mined as described by Clark et al. (12).
Lymphoscintigraphy was performed in
all patients. A quantity of 1 mCi (Tc99m-
dextran 500) in a 1-ml volume of 0.9% nor-
mal saline was injected intradermally in equal
parts into four quadrants around the biopsy
scar or primary tumor. The images were
obtained with a gamma camera with a high-
resolution collimator (Starcam 4000 600
X/RT). The projection of the SN was marked
on the overlying skin with indelible ink.
Surgery was performed 2 to 24 h after
lymphoscintigraphy. For the first 43 patients
the SN biopsy was based only on preopera-
tive lymphoscintigraphy and vital blue dye
mapping (Patent Blue V, Laboratoire
Guerbet, Aulnay-sous Bois, France).
Intraoperative gamma probe detection
(Neoprobe 1500, Columbus, OH, USA) was
added to the protocol for the remaining 315
patients. The node was considered to be an
SN if it was blue and/or showed counts five-
fold higher than background in vivo or ten-
fold higher ex vivo. After the SN was ex-
cised, the surgeon examined the operative
field with the probe. If there was 10% or
more capitation of the SN, the surgeon looked
for another node. The SN was trimmed of
excess fat and sectioned by the surgeon into
four fragments in the operating room. Two
noncontiguous fragments were sent to pa-
thology and the others were submitted to
molecular biology examination (RT-PCR for
tyrosinase mRNA). The histological exami-
nation consisted of hematoxylin-eosin stain-
ing and immunohistochemical markers for
S100 and HMB45. When hematoxylin-eosin
and/or immunohistochemical study showed
the presence of micrometastases in the SN,
complete lymphadenectomy was performed.
Patients with a negative SN were just followed
up. The median follow-up was 37 months.
Fisher’s exact test was applied to determine
the association between pathological fea-
tures and the occurrence of a positive SN.
The primary site was localized on the
head and neck, trunk and extremities in 14,
27 and 36 patients, respectively. The median
age of the 77 thin melanoma patients was
52.5 years. There were 34 male and 43 fe-
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male patients. Lymphoscintigraphy success-
fully identified the draining lymphatic basin
and SN in all 77 patients. On the basis of
vital dye and/or intraoperative gamma detec-
tion, 97.8% of the SN identified by
lymphoscintigraphy were found and excised.
Metastatic spread was diagnosed in six pa-
tients. We focused on these six patients com-
paring their pathological features with those
of 71 thin melanoma patients who did not
present micrometastases in the SN. Statisti-
cal analysis by the Fisher test showed that
ulceration (P = 0.019), high mitotic rate (P =
0.008) and vertical growth phase (P = 0.002)
were positively correlated with microme-
tastases (Table 1). All six patients with mi-
crometastases showed the vertical growth
phase in the primary lesion, five of them had
more than 5 mitoses/mm2, four of them had
ulceration, and three had regression. Addi-
tional characteristics of these six thin mela-
noma patients who presented SN metastases
are shown in Table 2.
The rate of occurrence of nodal metasta-
ses in our group of patients with thin mela-
noma (Breslow thickness 1 mm or smaller)
was 7.8% (6/77). All six patients showed the
vertical growth phase in their primary tumor.
These six patients underwent complete lym-
phadenectomy and none of them showed
another positive lymph node.
Previous publications have emphasized
that tumors with vertical growth phase need
Table 2. Characteristics of the six thin melanoma patients with sentinel node metastasis.
Patient 1 2 3 4 5 6
Sex F F F M M F
Age (years) 57 38 74 42 48 56
Site Trunk Trunk Extremity Extremity Trunk Trunk
Type Nodular SSM SSM SSM Nodular SSM
Breslow 0.8 0.5 0.6 0.4 0.9 0.8
Clark IV III IV III IV IV
Ulceration No Yes Yes Yes No Yes
Regression Yes Yes No No Yes No
>5 mitoses/mm2 Yes Yes No Yes Yes Yes
VGP Yes Yes Yes Yes Yes Yes
SSM = superficial spreading melanoma; VGP = vertical growth phase; F = female; M = male.
to be considered as high risk for regional
node metastasis (14,15). There is evidence
that thin melanoma with radial growth phase
does not metastasize (16,17). Our results
support that vertical growth phase, high mi-
totic rate and ulceration are indications for
SN biopsy. If other studies, with multivariant
analysis, confirm our results, more mela-
noma patients must be submitted to SN bi-
opsy (1,18).
Table 1. Sentinel node micrometastasis and patho-
logical features in 77 thin melanoma patients (1.0
mm).
Micrometastasis P*
No (N =71) Yes (N =6)
Clark 0.376
III 35 2
IV 36 4
Ulceration 0.019
Yes 13 4
No 58 2
Regression 0.084
Yes 12 3
No 59 3
>5 mitoses/mm2 0.008
Yes 18 5
No 53 1
VGP 0.002
Yes 22 6
No 49 0
VGP = vertical growth phase.
*Fisher test.
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